| Literature DB >> 24853323 |
Tiziano Tuccinardi1, Carlotta Granchi2, Flavio Rizzolio3, Isabella Caligiuri3, Vittoria Battistello2, Giuseppe Toffoli3, Filippo Minutolo2, Marco Macchia2, Adriano Martinelli2.
Abstract
Monoacylglycerol lipase is a serine hydrolase that play a major role in the degradation of 2-arachidonoylglycerol, an endocannabinoid neurotransmitter implicated in several physiological processes. Recent studies have shown the possible role of MAGL inhibitors as anti-inflammatory, anti-nociceptive and anti-cancer agents. The use of irreversible MAGL inhibitors determined an unwanted chronic MAGL inactivation, which acquires a functional antagonism function of the endocannabinoid system. However, the application of reversible MAGL inhibitors has not yet been explored, mainly due to the scarcity of known compounds possessing efficient reversible inhibitory activities. In this study we reported the first virtual screening analysis for the identification of reversible MAGL inhibitors. Among the screened compounds, the (4-(4-chlorobenzoyl)piperidin-1-yl)(4-methoxyphenyl)methanone (CL6a) is a promising reversible MAGL inhibitor lead (Ki=8.6μM), which may be used for the future development of a new class of MAGL inhibitors. Furthermore, the results demonstrate the validity of the methodologies that we followed, encouraging additional screenings of other commercial databases.Entities:
Keywords: Hydrolase; MAGL; Monoacylglycerol lipase inhibitors; Virtual screening
Mesh:
Substances:
Year: 2014 PMID: 24853323 DOI: 10.1016/j.bmc.2014.04.057
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641